Advertisement

Topics

Advantage Capital Partners Company Profile

04:47 EST 25th November 2017 | BioPortfolio

Advantage Capital Partners is a leading venture capital and small business finance firm focused on providing growth capital and other investments supporting state and local economic development efforts. The firm's typical forms of investment include early stage, expansion equity, mezzanine financing, senior and subordinated loans and government-guaranteed lending. With offices and partners in Austin, New Orleans, St. Louis, and other U.S. cities, Advantage has raised more than $1.3 billion in institutional capital since 1992 and invested in companies located in geographic areas underserved by traditional capital.


News Articles [1185 Associated News Articles listed on BioPortfolio]

Israeli genetic data co Genoox raises $6m

The round was led by led by Inimiti Capital Partners and Glilot Capital Partners.

MorphoSys-Aktie: Short-Attacke! Leerverkäufer GSA Capital Partners baut Shortposition auf - Aktiennews

Martinsried - Leerverkäufer GSA Capital Partners LLP geht Netto-Leerverkaufsposition in MorphoSys-Aktien ein: Die Leerverkäufer des Hedgefonds GSA Capital Partners LLP attackieren die Aktien des Bi....

M&As this week: Court Square Capital Partners, Quotient Sciences Limited, Jinzi Ham

Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors. Both Court...Read More... The post M&As this week: Court...

Paul Capital Partners: Financing and Risk Sharing

In this episode of PharmaTelevision News Review, Fintan Walton talks with Ken MacLeod, Partner at Paul Capital Partners. Filmed at BioTrinity 2010 in Newbury, UK.

Brandon Capital Partners: Dr David Fisher discusses their role in Medical Research Commercialization Fund

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr David Fisher, Venture Partner of Brandon Capital Partners

Apellis raises $60mm in Series E round

Apellis Pharmaceuticals Inc. (immunotherapies for autoimmune and inflammatory diseases) raised $60mm through its Series E round. Sectoral Asset Management led and was joined by new investors Sofinnova...

Forbion Capital Partners: Geert-Jan Mulder. Optimising commercial potential of portfolio company's products and technologies

In this episode of PharmaTelevision News Review, filmed at BioEurope 2012 in Hamburg, Germany, Fintan Walton talks to Geert-Jan Mulder, General Partner at Forbion Capital Partners

Chris Nave, Brandon Capital Partners: Passionate about turning innovative science into improved medical outcomes

In this interview filmed at Ausbiotech in Brisbane, Fintan Walton talks to Chris Nave, Managing Director, Brandon Capital Partners. Brandon Capital Partners makes seed and venture capital investments ...

PubMed Articles [468 Associated PubMed Articles listed on BioPortfolio]

A Tale of Two Towns: A Comparative Study Exploring the Possibilities and Pitfalls of Social Capital among People Seeking Recovery from Substance Misuse.

Social capital has become an influential concept in debating and understanding the modern world. Within the drug and alcohol sector, the concept of 'recovery capital' has gained traction with research...

Perceptions of community, social capital, and how they affect self-reported health: a multilevel analysis.

The link between social capital and self-reported health has been widely explored. On the other hand, we know less about the relationship between social capital, community socioeconomic characteristic...

Recovery capital pathways: Modelling the components of recovery wellbeing.

In recent years, there has been recognition that recovery is a journey that involves the growth of recovery capital. Thus, recovery capital has become a commonly used term in addiction treatment and r...

The dark side of social capital: A systematic review of the negative health effects of social capital.

There is a growing literature demonstrating the health benefits of social capital (defined as the resources accessed through social connections). However, social capital is also acknowledged to be a "...

Partners' Overestimation of Patients' Pain Severity: Relationships with Partners' Interpersonal Responses.

The present study examined whether concordance between patients' and their partners' reports of patient pain severity relates to partners' social support and behavioral responses in couples coping wit...

Clinical Trials [613 Associated Clinical Trials listed on BioPortfolio]

A Study of the Effects of Advantage 24 on the Rectum

The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Adv...

Slipped Capital Femoral Epiphysis Treatment

Slipped capital femoral epiphysis represents approximately 10.8 cases per 100,000 children. The primary source for the blood supply of the head of the femur is the deep branch of the media...

Partners Demonstration Project of PrEP and ART

The purpose of this protocol is to determine user preferences for antiretroviral therapy (ART) for HIV-1 infected partners and pre-exposure prophylaxis (PrEP) HIV-1 un-infected partners an...

Teachers and Parents as Partners During Middle School

There are two aims of this study (a) to examine the effect of Teachers and Parents as Partners on student, parent, and teacher outcomes in middle school and (b) identify barriers and facil...

Treatment for Men Who Are Abusive to Their Partners

This study will develop an individual behavior therapy for men who are violent toward their partners and will compare the therapy to standard group treatment.

Companies [2163 Associated Companies listed on BioPortfolio]

Advantage Capital Agribusiness Partners, LP

Advantage Capital Agribusiness Partners, LP (ACAP) is a $154.5-million fund that is licensed as a Rural Business Investment Company (RBIC) by the U.S. Department of Agriculture (U...

Advantage Capital Partners

Advantage Capital Partners is a leading venture capital and small business finance firm focused on providing growth capital and other investments supporting state and local...

Nascent Pharmaceuticals, Inc.

Nascent Pharmaceuticals, Inc. is a privately held company funded by individual and institutional investors.Nascent’s lead institutional investor is Advantage Capital Partners, a private equity firm....

Oak Hill Capital Partners

Oak Hill Capital Partners is a private equity firm with more than $8.2 billion of committed capital from leading entrepreneurs, endowments, foundations, corporations, pension fund...

Thompson Street Capital Partners

Thompson Street Capital Partners has $450 million in capital under management. The private equity firm makes investments in manufacturing, service and distribution businesses. The fund's philosophy is...

More Information about "Advantage Capital Partners" on BioPortfolio

We have published hundreds of Advantage Capital Partners news stories on BioPortfolio along with dozens of Advantage Capital Partners Clinical Trials and PubMed Articles about Advantage Capital Partners for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advantage Capital Partners Companies in our database. You can also find out about relevant Advantage Capital Partners Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record